 |
160 Products |  |
813 Diseases | | 160 Products |
|
1618 Trials |  |
78436 News |  |
| «12...898899900901902903904905906907908...910911» |
- Kepivance (palifermin) / SOBI, Amgen
New P1 trial: Melphalan & Palifermin Followed by Peripheral Blood Stem Cell Transplant in Treating Pts w/Stage II-III Multiple Myeloma (clinicaltrials.gov) - Jul 30, 2012
P1, N=38, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
- Enbrel (etanercept) / Pfizer, Amgen
Trial completion: RACAT: Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy (clinicaltrials.gov) - Jul 30, 2012
P=N/A, N=353, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed
- TTP607 / vTv Therapeutics
Enrollment change, Metastases: TTP607 in Refractory Solid Malignancies (clinicaltrials.gov) - Jul 26, 2012
P1, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=40 --> 0
- |||||||||| Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
New P3 trial: START-CKD: Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease (clinicaltrials.gov) - Jul 26, 2012
P3, N=750, Recruiting, Sponsor: Amgen
- ||||| Repatha (evolocumab) / Amgen, Astellas
New P2 trial: A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects (clinicaltrials.gov) - Jul 26, 2012
P2, N=310, Completed, Sponsor: Amgen
- | fipaxalparant (AMG 670) / Amgen
New P2 trial: Proof of Biological Activity of SAR100842 in Systemic Sclerosis (clinicaltrials.gov) - Jul 24, 2012
P2, N=30, Active, not recruiting, Sponsor: Sanofi
- New P1/2 trial: A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse). (EUDRACT) - Jul 24, 2012
P1/2, N=36, Ongoing, Sponsor: TACL
- Actimmune (interferon gamma-1 b) / Clinigen, Amgen
New P3 trial, IO biomarker: The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis (clinicaltrials.gov) - Jul 23, 2012
P3, N=20, Recruiting, Sponsor: Radboud University
- ||||| Ryzneuta (efbemalenograstim alpha) / Yifan Pharma
New P2 trial: Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy (clinicaltrials.gov) - Jul 22, 2012
P2, N=200, Recruiting, Sponsor: Generon (Shanghai) Corporation Ltd.
- | Enrollment change: IBCSG-15-95: High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer (clinicaltrials.gov) - Jul 19, 2012
P3, N=344, Completed, Sponsor: International Breast Cancer Study Group
N=40 --> 0 N=210 --> 344
- ||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Neulasta (pegfilgrastim) / Roche
Enrollment open: Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation (clinicaltrials.gov) - Jul 19, 2012
P=N/A, N=60, Recruiting, Sponsor: Centre Leon Berard
N=210 --> 344 Not yet recruiting --> Recruiting
- | Trial completion: IBCSG-15-95: High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer (clinicaltrials.gov) - Jul 19, 2012
P3, N=344, Completed, Sponsor: International Breast Cancer Study Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Enbrel (etanercept) / Pfizer, Amgen
New P4 trial, Real-world evidence, Real-world: Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry (clinicaltrials.gov) - Jul 18, 2012
P4, N=1, Completed, Sponsor: Pfizer
- | Stivarga (regorafenib) / Bayer
New P3 trial, Stroma: Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (clinicaltrials.gov) - Jul 18, 2012
P3, N=0, No Longer Available, Sponsor: Bayer
- |||||||||| Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
New P3 trial: A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) (clinicaltrials.gov) - Jul 18, 2012
P3, N=1225, Active, not recruiting, Sponsor: Eli Lilly and Company
- | Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin, Monofer (iron isomaltoside 1000) / Pharmacosmos
New P2 trial, Surgery: Treatment of a low blood count before heart surgery comparing iron supplements taken by mouth and the combination of iron given by intravenous drip and a drug to increase the blood count (EUDRACT) - Jul 18, 2012
P2, N=350, Completed, Sponsor: Brighton & Sussex University Hospitals NHS Trust
- || Enrollment closed: AALL02P2: Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes (clinicaltrials.gov) - Jul 17, 2012
P=N/A, N=168, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Suspended --> Active, not recruiting
- Yondelis (trabectedin) / PharmaMar, J&J, Neulasta (pegfilgrastim) / Roche
Trial completion: Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (clinicaltrials.gov) - Jul 17, 2012
P2, N=70, Completed, Sponsor: Gynecologic Oncology Group
Suspended --> Active, not recruiting Active, not recruiting --> Completed
- || filanesib (ARRY-520) / Pfizer
Enrollment change: A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 16, 2012
P1, N=90, Recruiting, Sponsor: Array BioPharma
Active, not recruiting --> Completed N=45 --> 90
- ||| HyPoietin (epoetin alfa biosimilar) / GC Biopharma, Genexine, Fosun Pharma
Trial completion: To Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Erythropoietin (clinicaltrials.gov) - Jul 16, 2012
P1, N=100, Completed, Sponsor: Green Cross Corporation
N=45 --> 90 Active, not recruiting --> Completed
- ||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: DIRECT: Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis (clinicaltrials.gov) - Jul 16, 2012
P3, N=1262, Completed, Sponsor: Daiichi Sankyo Co., Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | litronesib (KF 89617) / Kyowa Kirin, Eli Lilly
Trial completion, Metastases: A Dose-Escalation Study for Patients With Advanced Cancer (clinicaltrials.gov) - Jul 12, 2012
P1, N=50, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| litronesib (KF 89617) / Kyowa Kirin, Eli Lilly
Trial completion, Metastases: A Study for Participants With Advanced Cancer (clinicaltrials.gov) - Jul 12, 2012
P1, N=70, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Kepivance (palifermin) / SOBI, Amgen
Trial completion: Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE) (clinicaltrials.gov) - Jul 12, 2012
P3, N=47, Completed, Sponsor: Swedish Orphan Biovitrum
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Kepivance (palifermin) / SOBI, Amgen
Trial initiation date, Metastases: Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Jul 11, 2012
P3, N=188, Active, not recruiting, Sponsor: Swedish Orphan Biovitrum
Active, not recruiting --> Completed Initiation date: Jan 2005 --> Aug 2005
- Thalagen (autologous CD34+ cells transduced with TNS9.3.55) - San Rocco Therap, Memorial Sloan / Kettering Cancer Center
New P1 trial, Viral vector: (clinicaltrials.gov) - Jul 11, 2012
P1, N=10, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- ||| AMB-05X / AmMax
Enrollment open, Metastases: A Study of AMG 820 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Jul 11, 2012
P1, N=62, Recruiting, Sponsor: Amgen
Initiation date: Jan 2005 --> Aug 2005 Not yet recruiting --> Recruiting
- | Cresemba (isavuconazonium sulfate) / Astellas, Basilea, Pfizer, Laboratoire Riva, Asahi Kasei
Trial completion: Drug Interaction Study of Isavuconazole and Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone (clinicaltrials.gov) - Jul 11, 2012
P1, N=24, Completed, Sponsor: Astellas Pharma Global Development, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- New P2 trial: Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer (clinicaltrials.gov) - Jul 10, 2012
P2, N=0, Withdrawn, Sponsor: University of Southern California
- Actimmune (interferon gamma-1 b) / Clinigen, Amgen
New P2 trial: IFN_BOSZT_01: A Phase II Trial on Treatment of Steroid-refractory Bronchiolitis Obliterans With Interferon Gamma 1b After Allogeneic SCT (clinicaltrials.gov) - Jul 10, 2012
P2, N=10, Active, not recruiting, Sponsor: University Hospital Regensburg
- docetaxel / Generic mfg., gemcitabine / Generic mfg.
New P2 trial, Metastases: Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma (clinicaltrials.gov) - Jul 10, 2012
P2, N=40, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- | doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg., gemcitabine / Generic mfg.
Enrollment open, Surgery: GOG study : Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery (clinicaltrials.gov) - Jul 10, 2012
P3, N=216, Recruiting, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed: GIST: Study to Determine The Effect of a Drug Called Neupogen on Stroke Recovery (clinicaltrials.gov) - Jul 10, 2012
P1, N=20, Active, not recruiting, Sponsor: Ottawa Hospital Research Institute
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion, Adherence: PROVE: Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis (clinicaltrials.gov) - Jul 10, 2012
P=N/A, N=303, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: DOSERA: Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA (clinicaltrials.gov) - Jul 10, 2012
P4, N=91, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Herceptin (trastuzumab) / Roche
Trial completion: Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery (clinicaltrials.gov) - Jul 10, 2012
P2, N=60, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | pegfilgrastim biosimilar / Hangzhou Jiuyuan Gene Engineering
New P1 trial: Pharmacokinetics and Pharmacodynamics Study of Pegfilgrastim in Chemotherapy Patients (clinicaltrials.gov) - Jul 9, 2012
P1, N=24, Recruiting, Sponsor: Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Surgery: SWOG-EORTC-62933: Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 9, 2012
P3, N=340, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Vectibix (panitumumab) / Amgen
New P2 trial: Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies (clinicaltrials.gov) - Jul 4, 2012
P2, N=0, Withdrawn, Sponsor: Athanassios Argiris
- |||| Vectibix (panitumumab) / Amgen
Enrollment open: PARLIM: Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients (clinicaltrials.gov) - Jul 4, 2012
P2, N=111, Recruiting, Sponsor: PD Dr. med. Volker Heinemann
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- trebananib (AMG 386) / Amgen, Avastin (bevacizumab) / Roche
Trial initiation date: Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors (clinicaltrials.gov) - Jul 3, 2012
P2, N=141, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Initiation date: Dec 2011 --> Jun 2012
- ||| Vectibix (panitumumab) / Amgen
Trial initiation date: PROVE: Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - Jul 1, 2012
P2, N=140, Recruiting, Sponsor: WiSP Wissenschaftlicher Service Pharma GmbH
Initiation date: Dec 2011 --> Jun 2012 Initiation date: Jul 2011 --> Oct 2011
- ||| trebananib (AMG 386) / Amgen, Avastin (bevacizumab) / Roche
Enrollment change: Amgen 386 for Recurrent Glioblastoma (clinicaltrials.gov) - Jul 1, 2012
P1/2, N=86, Recruiting, Sponsor: Dana-Farber Cancer Institute
Initiation date: Jul 2011 --> Oct 2011 N=68 --> 86
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment change: Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease (clinicaltrials.gov) - Jul 1, 2012
P2, N=70, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=68 --> 86 N=50 --> 70
- |||| Vectibix (panitumumab) / Amgen
Enrollment open: PROVE: Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - Jul 1, 2012
P2, N=140, Recruiting, Sponsor: WiSP Wissenschaftlicher Service Pharma GmbH
N=50 --> 70 Not yet recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial termination, Metastases: Chemotherapy Plus Interferon Alfa Alone or With Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jun 28, 2012
P3, N=469, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; low accrual
- |||||||||| Repatha (evolocumab) / Amgen, Astellas
New P3 trial, HEOR: FOURIER: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (clinicaltrials.gov) - Jun 28, 2012
P3, N=22500, Ongoing, Sponsor: Amgen Inc`AMGEN INC.
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Amsidine (amsacrine) / Kyowa Kirin
Trial completion: Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 28, 2012
P3, N=500, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Terminated; low accrual Active, not recruiting --> Completed
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P3 trial: ARCH: Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Jun 27, 2012
P3, N=4000, Recruiting, Sponsor: Amgen
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P2 trial: Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty (clinicaltrials.gov) - Jun 26, 2012
P2, N=64, Recruiting, Sponsor: Hans Mallmin